E-LIB Suche - Ergebnisse für: Marco Montillo

1

Localization of Aspergillosis to the Central Nervous System..:

Livio Pagano ; Paolo Ricci ; Marco Montillo...
Clinical Infectious Diseases. 23 (1996) 3 - p. 628-630 , 1996

Link: https://www.jstor.org/st..

2

Activity of venetoclax in patients with relapsed or refract..:

Kater, Arnon P ; Arslan, Önder ; Demirkan, Fatih...
The Lancet Oncology. 25 (2024) 4 - p. 463-473 , 2024

Link: https://doi.org/10.1016/..

3

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, ..:

Frustaci, Anna Maria ; Montillo, Marco ; Rossi, Davide...
HemaSphere. 7 (2023) S3 - p. e6990566 , 2023

Link: https://doi.org/10.1097/..

4

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALY..:

Kater, Arnon ; Harrup, Rosemary ; Kipps, Thomas J...
HemaSphere. 7 (2023) S3 - p. e492813f , 2023

Link: https://doi.org/10.1097/..

5

Next Generation BTK Inhibitors in CLL: Evolving Challenges ..:

Frustaci, Anna Maria ; Deodato, Marina ; Zamprogna, Giulia...
Cancers. 15 (2023) 5 - p. 1504 , 2023

Link: https://doi.org/10.3390/..

6

Enduring undetectable MRD and updated outcomes in relapsed/..:

Seymour, John F. ; Kipps, Thomas J. ; Eichhorst, Barbara F....
Blood. 140 (2022) 8 - p. 839-850 , 2022

Link: https://doi.org/10.1182/..

7

Coexisting conditions and concomitant medications do not af..:

Frustaci, Anna Maria ; Del Poeta, Giovanni ; Visentin, Andrea...
Therapeutic Advances in Hematology. 13 (2022) - p. 204062072211275 , 2022

Link: https://doi.org/10.1177/..

8

Impact of the Types and Relative Quantities of IGHV Gene Mu..:

Kaufman, Matthew ; Yan, Xiao-Jie ; Li, Wentian...
Frontiers in Oncology. 12 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

9

SOHO State of the Art Updates and Next Questions: What is F..:

Frustaci, Anna Maria ; Deodato, Marina ; Zamprogna, Giulia...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) 6 - p. 356-361 , 2022

Link: https://doi.org/10.1016/..

10

Do age, fitness, and concomitant medications influence mana..:

Tedeschi, Alessandra ; Frustaci, Anna Maria ; Mauro, Francesca Romana...
Blood Advances. 5 (2021) 24 - p. 5490-5500 , 2021

Link: https://doi.org/10.1182/..

11

Tafasitamab combined with idelalisib or venetoclax in patie..:

Staber, Philipp Bernhard ; Jurczak, Wojciech ; Greil, Richard...
Leukemia & Lymphoma. 62 (2021) 14 - p. 3440-3451 , 2021

Link: https://doi.org/10.1080/..

12

Efficacy of idelalisib and rituximab in relapsed/refractory..:

Rigolin, Gian Matteo ; Cavazzini, Francesco ; Piciocchi, Alfonso...
Hematological Oncology. 39 (2021) 3 - p. 326-335 , 2021

Link: https://doi.org/10.1002/..

13

Risk factors for grade 3/4 transaminase elevation in patien..:

Brown, Jennifer R. ; Zelenetz, Andrew ; Furman, Richard...
Leukemia. 34 (2020) 12 - p. 3404-3407 , 2020

Link: https://doi.org/10.1038/..

14

Five‐year survival follow‐up of a phase III randomised tria..:

Miklos, Udvardy ; Strugov, Vladimir ; Lewerin, Catharina...
British Journal of Haematology. 189 (2020) 4 - p. 689-693 , 2020

Link: https://doi.org/10.1111/..

15

A five‐year follow‐up of untreated patients with chronic ly..:

Offner, Fritz ; Robak, Tadeusz ; Janssens, Ann...
British Journal of Haematology. 190 (2020) 5 - p. 736-740 , 2020

Link: https://doi.org/10.1111/..